Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation

被引：0
|
作者：
Andronikou, Christina
Burdova, Kamila
Dibitetto, Diego
Lieftink, Cor
Beijersbergen, Roderick L.
Hanzlikova, Hana
Jonkers, Jos
Rottenberg, Sven
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-LB_A25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB_A25
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
  • [22] Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors.
    McKean, Meredith
    Tolcher, Anthony W.
    Reeves, James Andrew
    Chmielowski, Bartosz
    Shaheen, Montaser F.
    Beck, Joseph Thaddeus
    Orloff, Marlana M.
    Somaiah, Neeta
    Van Tine, Brian Andrew
    Drabick, Joseph J.
    Spira, Alexander I.
    O'byrne, Kenneth
    Karapetis, Christos Stelios
    Foresto, Steven A.
    Movva, Sujana
    Martinez, Jose
    Li, Mingyu
    Winkler, Robert
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] The efficacy and safety of a selective PARP1 inhibitor ACE-86225106 in patients with advanced solid tumors: preliminary results from a first-in-human phase 1/2 study
    Liu, S.
    Zhang, J.
    Chen, Z.
    Zhang, Y.
    Wang, J.
    Chen, Y.
    Chen, J.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S32 - S32
  • [24] Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
    Naito, Yoichi
    Nakamura, Seigo
    Kawaguchi-Sakita, Nobuko
    Ishida, Takanori
    Nakayama, Takahiro
    Yamamoto, Yutaka
    Masuda, Norikazu
    Matsumoto, Koji
    Kogawa, Takahiro
    Sudo, Kazuki
    Shimomura, Akihiko
    Lai, Catherine
    Zhang, Danjie
    Iwahori, Yuki
    Gary, Dianna
    Huynh, Danh
    Iwata, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (11) : 1684 - 1695
  • [25] Updated results from a Phase I study of AV-951 (KRN951), a potent and selective VEGFR-1,-2 and-3 tyrosine kinase inhibitor, in patients with advanced solid tumors
    Eskens, Ferry A. L. M.
    de Jonge, Maja J. A.
    Esteves, Brooke
    Cotreau, Monette
    Bhargava, Pankaj
    Ryan, John
    van Doorn, Leny
    Isoe, Toshiyuki
    Hayashi, Kunihiko
    Ekman, Lena
    Burger, Herman
    Verweij, Jaap
    CANCER RESEARCH, 2008, 68 (09)
  • [26] Optimizing the therapeutic index of HDM2 inhibition: Results from a dose-and regimen-finding Phase I study of NVP-HDM201 in pts with TP53 wt advanced tumors
    Hyman, David M.
    Chatterjee, Manik
    de Vos, Filip
    Lin, Chia-Chi
    Suarez, Cristina
    Tai, David
    Cassier, Philippe
    Yamamoto, Noboru
    de Weger, Vincent A.
    Jeay, Sebastien
    Meille, Christophe
    Halilovic, Ensar
    Mariconti, Luisa
    Klopfenstein, Matthieu
    Guerreiro, Nelson
    Radhakrishnan, Rajkumar
    Kuriakose, Emil T.
    Bauer, Sebastian
    CANCER RESEARCH, 2017, 77
  • [27] The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study
    LoRusso, Patricia
    Yamamoto, Noboru
    Patel, Manish R.
    Laurie, Scott A.
    Bauer, Todd M.
    Geng, Junxian
    Davenport, Teffany
    Teufel, Michael
    Li, Jian
    Lahmar, Mehdi
    Gounder, Mrinal M.
    CANCER DISCOVERY, 2023, 13 (08) : 1802 - 1813
  • [28] Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion.
    Cleary, James M.
    Iyer, Gopa
    Oh, Do-Youn
    Mellinghoff, Ingo K.
    Goyal, Lipika
    Ng, Matthew C. H.
    Meric-Bernstam, Funda
    Matos, Ignacio
    Chao, Tsu-Yi
    Sarkouh, Rafik Ait
    Cretegny, Kira
    Nicolas-Metral, Valerie
    Pokorska-Bocci, Anna
    Vaslin, Anne
    Zanna, Claudio
    Zubel, Angela
    Tabernero, Josep
    Flaherty, Keith
    Hyman, David Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] Results of study PX-171-007 a phase 1b/2 study of carfilzomib, a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors
    Gordon, M.
    Infante, J.
    Papadopoulos, K. P.
    Lee, P.
    Sausville, E.
    Mendelson, D.
    Wong, A. F.
    Vallone, M.
    Rosen, P. J.
    Burris, H.
    EJC SUPPLEMENTS, 2009, 7 (02): : 122 - 123
  • [30] Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study
    De La Fuente, Macarena Ines
    Ahnert, Jordi Rodon
    Yaeger, Rona
    Tsai, Frank Yung-Chin
    Janku, Filip
    Butowski, Nicholas A.
    Allen, Carl E.
    Ammakkanavar, Natraj Reddy
    Taylor, Jennie Webster
    Michelson, Glenn
    Kline, Irina
    Paz, Michael
    Tussay-Lindenberg, Alexia
    Wong, Kongming
    Shepherd, Stacie Peacock
    Jiang, Ping
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345